Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this survey is designed to investigate the treatment status of hypertensive patient with metabolic syndrome-related risk factors treated with candesartan cilexetil tablets (Blopress Tablets), as well as to assess relationships between risk factors (example, visceral fat accumulation) and the incidence of cerebrovascular/cardiovascular events in an exploratory manner.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria: Hypertensive patients with at least one of the following risk factors:

• Waist circumference greater than or equal to (≥) 85 centimeter (cm) for male and ≥ 90 cm for female

• Fasting triglyceride level ≥ 150 milligram per deciliter (mg/dL)

• High-density lipoprotein (HDL) cholesterol level less than (<) 40 mg/dL

• Fasting blood glucose level ≥ 110 mg/dL

• Body-mass index (BMI) ≥ 25.0 * Patients currently taking medications for hypertriglyceridemia, hypo-HDL-cholesterolemia, or diabetes mellitus are also regarded as meeting the criteria for inclusion in the surveillance

Exclusion Criteria: Hypertensive patients who meet all of the following conditions ([1] to [3]):

1. Patients receiving continuous therapy with Blopress Tablets

2. Patients aged < 20 years or ≥ 75 years

3. Patients with a history of cerebrovascular or coronary artery disease within 6 months before the start of the surveillance